CG Oncology develops cretostimogene via rolling BLA, phase 3 PIVOT-006 data in 1H 2026, and $680M cash into 2028. Find out ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...
Morning Overview on MSN
Why cancer returns years later, and how we can stop it
Cancer’s cruelest trick is its ability to disappear, only to reappear years later in a new organ or a familiar scar. The fear ...
An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.
2d
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead ...
A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...
New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...
Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...
Patients recently diagnosed with cancer show an increased risk for major bleeding after myocardial infarction, with the risk ...
CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that utilizes artificial intelligence ...
Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback